Biography & Education

Biography
My primary goal is to provide optimal balance of appropriate, aggressive treament and a good quality of life. This requires individualized plans based on a patients particular goals and medical issues.
Specialties
  • Oncology - Medical
Education Background
Fellowship: University of Washington, WA - Medical Oncology; Fred Hutchinson Cancer Research Center, WA
Medical School: Harvard Medical School
Residency: Brigham and Womens Hospital
Languages
  • Vietnamese
  • Chinese
  • English
  • Korean
  • Spanish

Care Locations

Medical Oncology / Ballard - SCI
5300 Tallman Ave NW
3rd Main Floor
Seattle 98107
Fax 206-781-6011
5300 Tallman Ave NW
2 North
Seattle, WA 98107
Fax 206-781-6011
1221 Madison Street
Arnold Pavilion, Suite 200
Seattle, WA 98104
Swedish Cancer Institute-Medical Oncology
1221 Madison St.
Suite 200
Seattle 98104
Fax (206) 386-2746
Accepted Payment Methods
Medicare, Medicaid/DSHS, Bill Insurance, VISA, Master Card, Cash, Check, American Express, Billing Service, Discover Card, Money Order
Accepting Medicaid

Publications

Research

CLINICAL TRIALS:

Dr. Howard (Jack) West is the lead investigator for the following clinical trials currently available at the Swedish Cancer Institute:

A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors

A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib

________________________________________

PUBLICATIONS:

Green, MR. West H, & Socinski, MA. Impact of the ASCO 2007 Presentat ion of HOG Lun 01-24 / USO-023 on the Prescribi ng Plans of American Med ical Oncologists for Patients with Stage IIIB Non-small Cell Lung Cancer. J Thor Oncol 2009; 4: 983-987.

West H, Harpole D, & Travis W. Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. CHEST, 2009: 136; 1112-1118.

West HL, Wakelee HA, Perry MC, Belt RJ, Chen R, & Obasaju C. Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small cell lung cancer: A phase II clinical trial. Annals of Oncology 2009; 20: 850 -856.

Chen G, Huynh H, Fehrenbacher L, West H, Lara, PN, Yavorkovsky LL, Russin M, Goldstein D, Gandara D, & Lau D. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. Journal of Clinical Oncology, 2009; 27: 1401 – 1404.

Garfield DH, Cadranel J, & West HL. Bronchioloalveolar carcinoma: The case for two diseases. Clinical Lung Cancer, 2008: 9: 24-29.

Hirsch F, Varella-Garcia M, Capuzzo F, McCoy J, Bemis L, Xamier A, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar A, Crino L, Gandara D, Franklin W, & Bunn P, Jr. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology, 18:752-760, 2007.

West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crow l ey JJ, & Gandara DR. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. Journal of Clinical Oncology 24: 1807-1813, 2006.

Hirsch FR, Varella-Garcia M. McCoy J, West H, Xavier, AC, Gumerlock P, Bunn PA, Franklin WA, Crowley J, & Gandara DR. Increased EGFR gene copy number detected by FISH is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126). Journal of Clinical Oncology 2005; 23: 6838-6845, 2005.

West HL, Crowley JJ, Vance RB, Franklin WA, Livingston RB, Dakhil SR, Giguerre JK, Rivkin SE, Kraut M, Chansky K, & Gandara DR. Advanced brocnhioloalveolar carcinoma: A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714). Annals of Oncology, 2005; 16: 1076-1080.

Gandara DR, West H, Chansky K, Davies AM, Lau DHM, Crowley J, Gumerlock PH, & Franklin
W. Bronchioloalveolar carcinoma: A model for investigating the biology of EGFR Inhibition. Clinical Cancer Research, 2004; 10: 4205s-4209s.

Garrison JA, McCune JS, Livingston RB, Linden HM, Gralow JR, Ellis GK, & West HL. Myalgias & arthralgias associated with paclitaxel: A review of incidence and management. Oncology, 2003; 17: 271-277.

Disis ML, West HL, & Schiffman K. Cancer vaccines for the treatment and prevention of non-small cell lung cancer. Clinical Lung Cancer, 2000; 1: 294-301.

Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, & Hyman BT. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Annals of Neurology, 1997; 41: 17-24.

Gomez-Isla T, West HL, Rebeck GW, Harr SD, Growden JH, Locasio JT, Perls T, Lipsitz, LA, & Hyman BT. Clinical and pathological correlates of apolipoprotein E e4 in Alzheimer’s disease. Annals of Neurology, 1996; 39: 62-70.

Hyman BT, West HL, Rebeck GW, Buldyrev SV, Mantegna RN, Ukleja M, Havlin S, & Stanley HE. Quant-itative analysis of senile plaques in Alzheimer’s disease: Observation of log¬normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21(Down syndrome). Proceedings of the National Academy of Sciences USA, 1995; 92: 3586-3590.

Hyman BT, West HL, Rebeck GW, Lai F, & Mann DMA. Neuropathological changes in Down syndrome hippocampal formation: effect of age and apolipoprotein E genotype. Archives of Neurology, 1995; 52: 373-378.

Rebeck GW, Perls TP, West HL, Sodhi P, Lipsitz LA, & Hyman BT. Reduced apolipoprotein e4 allele frequency in the oldest old Alzheimer’s patients and cognitively normal patients. Neurology, 1994; 44: 1513-1516.

West HL, Rebeck GW, & Hyman BT. Frequency of the apolipoprotein E e2 allele is diminished in sporadic Alzheimer’s disease. Neuroscience Letters; 175: 46-48.

Marston HM, West HL, Wilkinson, LJ, Everitt BJ, & Robbins TW. Effects of cytotoxic lesions of the medial septum and vertical limb nucleus of the diagonal band of Broca on conditional visual discrimination: Relationship between discrimination performance and choline acetyltransferase activity in the cingulate cortex. Journal of Neuroscience, 1994: 14:2009-2019.

West HL, Mark GP, & Hoebel, BG. Effects of conditioned taste aversion on extracellular serotonin in the lateral hypothalamus and hippocampus of freely moving rats. Brain Research, 1991; 556: 95-100.
Hoebel BG, Mark GP, & West HL. Conditioned neurotransmitter release. Symposium on Regulation of Food Intake, Metabolism, and Energy Balance, 1990; 4: 36.
________________________________________

INVITED MANUSCRIPTS/CHAPTERS:

West H, & Camidge DR. Have mutation, will travel: Utilizing online patient communities and new trial strategies to optimize clinical research in the era of molecularly diverse oncology. J Thor Oncol 2012: 7: 482-484.

West H. The evolving role of targeted therapy in early stage and locally advanced non-small cell lung cancer. In T Mekhail, Ed., Curr Oncol Rep, 2011, 13: 280-289..

West H. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: Incremental benefit, debatable value. J Clin Oncol 2011; 29: 1095-1098.

Stinchecombe TE & West HL. Maintenance therapy in non-small-cell lung cancer. Lancet 2009; 374: 1398-1400.

West H. The role for surgery in stage III non–small-cell lung cancer: Can we reliably select the right patients? Clin Lung Cancer 2009; 10: 314-316.

West H, Lilenbaum R, Harpole D, et al. Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J Thor Oncol 2009; 4 (suppl 2): S1029-1039.

West H & Garfield DH. Bronchioloalveolar Carcinoma: Not as East as “BAC”. J Thor Oncol, 2009; 4: 1047-1048.

Einhorn LH, Bonomi P, Bunn PA, Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, West H, & Herbst RS. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. J Thor Oncol 2008; 3: 545-555.

West, H. Gefitinib in advanced bronchioloalveolar carcinoma (BAC): A case study and review of clinical research on EGFR tyrosine kinase inhibitor therapy for BAC. American Journal of Hematology/Oncology, 2006 5 (suppl 10): 9-12.

Kris MG, Giaccone G, Davies A, Fukuoka M, Garfield DH, Jassem J, Quoix EA, Sandler AB, Scagliotti GV, Van Meerbeeck JP, & West H. Systemic therapy of bronchioloalveolar carcinoma: results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma. Journal of Thoracic Oncology, 2006, 1: S32-S36.

West H. Emerging approaches to advanced bronchioloalveolar carcinoma. Current Treatment Options in Oncology, 2006; 7: 69-76.

West H. EGFR inhibitors fight BAC (Editorial). Signal, 2005; 1: 18-20.

West H & Albain KS. Current standards and ongoing controversies in the management of locally advanced non-small cell lung cancer. Seminars in Oncology, 2005; 32: 284-292.

West H & Garfield D. Bronchioloalveolar Carcinoma: New insights in epidemiology, pathology, and novel strategies. Update chapter for HI Pass, JB Mitchell, DH Johnson, AT Turrisi, & John Minna (Eds.), Lung Cancer: Principles and Practice. Philadelphia: Lippincott, Williams, & Wilkins. Supplement, 2004.

West H. Incorporation of novel therapies into the management of locally advanced NSCLC. In R Govindan, Ed., Locally Advanced Non-Small-Cell Lung Cancer. New York: CMP Healthcare Media. 2004, pp. 95-105.

Gandara DR, West H, Albain KS, Werner-Wasik M, Crowley J, & Choy H. Defining the role of radiation therapy in Stage III non-small cell lung cancer: Rationale and design of a new intergroup study. American Society of Clinical Oncology 40th Annual Meeting Educational Book. 2004, pp. 458-462.

West H & Kelly K. Pleural malignancies and benign neoplasms of the lung. In ME Hanley & C Welsh, Eds., Current Medical Diagnosis and Treatment in Pulmonary Medicine. New York: Lange Medical Books/McGraw Hill. 2003, pp. 433-439.

Hyman BT, Gomez-Isla T, Rebeck GW, Briggs M, Chung H, West HL, Greenberg S, Mui S, Nichols S, Wallace R, & Growdon JH. Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer’s disease. Annals of the New York Academy of Sciences, 1996; 802: 1-5.

Hyman BT, Hedley-Whyte ET, Rebeck GW, Vonsattel JP, West HL, & Growdon JH. Apolipoprotein E 4/4 in a neuropathologically normal very elderly individual. Archives of Neurology, 1996; 53: 215.

Hyman BT, Gomez-Isla T, West H, Briggs M, Chung H, Growden JH, & Rebeck GW. Clinical and neuropathological correlates of apolipoprotein E genotype in Alzheimer’s disease: Window on molecular epidemiology. Annals of the New York Academy of Sciences, 1996; 777: 158-165.

Brendel D, West H, Hyman S. Hallucinogens. In: D Roberts & L Friedman, Eds., Source Book of Substance Abuse and Addiction. Baltimore, MD: Williams & Wilkins, 1995; pp. 217-230.

Hyman, BT, Sodhi, P, Harr SD, West HL, Simonian NA, Rebeck GW, Mui S, & Isla-Gomez T. The paradox of neurofibrillary tangles and senile plaques in Alzheimer’s disease. In: K Iqbal, JA Mortimer, B Winblad, & HM Wisniewski, Eds., Research Advances in Alzheimer’s disease and Related Disorders. Chichester, UK: John Wiley & Sons, 1995; pp. 453-460.

West HL, Rebeck GW, Growdon JH, & Hyman BT. Apolipoprotein E4 affects neuropathology but not clinical progression in Alzheimer’s disease. In: K Iqbal, JA Mortimer, B Winblad, & HM Wisniewski, Eds., Research Advances in Alzheimer’s disease and Related Disorders. Chichester, UK: John Wiley & Sons, 1995; pp. 363-370.

Mark GP, Schwartz, DH, Hernandez L, West HL, & Hoebel BG. Application of brain microdialysis to the study of motivation and conditioning: Measurements of dopamine and serotonin in freely-behaving rats. In: TE Robinson & JP Justice, Eds.: Microdialysis in Neuroscience. Amsterdam: Elsevier Science Publishing, 1993: pp. 131-136.

Hernandez L, Parada M, Baptista T, Schwartz D, West HL, Mark GP, & Hoebel BG. Hypothalamic serotonin in treatments for feeding disorders and depression as studied by brain microdialysis. Journal of Clinical Psychiatry, 1991; 52 Suppl.: 32-40.
________________________________________

ABSTRACTS:

West H, Moon J, Hirsch F, Mack PC, Wozniak A, Redman M, & Gandara DR. The combination of erlotinib/bevacizumab in never-smokers with advanced lung adenocarcinoma: Southwest Onc-ology Group (SWOG) trial 0636. J Thor Oncol 2011; 6(6) Suppl 2:S552-553 (A#MO-09-03-04).

Green MR, Wozniak AJ, Willey J, Lemke KE, & West HL. Plans of American medical oncologists (AMO) to order molecular testing before starting first-line therapy for patients with stage IV non-small cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology 28 15s (suppl., A#7568).

Wakelee H, Gettinger S, Engelman J, J�nne P, West H, Subramaniam D, Leach J, Wax M, Yaron Y, & Lara P. A phase 1b/2 study of XL184 (BMS 907351) with & without erlotinib (E) in patients (pts) with non-amall cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology 28 15s (suppl., A#3017).

Hanna NH, Estes D, Arnott J, Marcotte A, Hannah A, Sidor CF, West H, Clamon G, & Hoang T. Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology 2009; A#e19005.

West H, Chansky K, Franklin WA, .Hirsch FR, Crowley JJ, Lau DH, & Gandara DR. Long-term survival with gefitinib (ZD 1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126. Proceedings of the American Society of Clinical Oncology 2008; 26: A#8047.

Green MR, West H, Socinski MA, Willey J, Daniels L, Lemke K, Rafferty G, & Iovino L. Management of N3 stage IIIB NSCLC: Changes in US physician behavior following ASCO 2007. Proceedings of the American Society of Clinical Oncology 2008; 26: A#7579.

West H, Lee S , Reyno L, Fehrenbacher L, Cohn AL, Hopkins JO , Irwin DH, Smith DA, Boyd TE, & Olsen MR. DN101-004: A multicenter, open label, dose ranging study of DN-101 and docetaxel in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. Journal of Thoracic Oncology 2007; 2(8) Suppl 4:S334 (A#B1-04)

West H, Lee S , Reyno L, Fehrenbacher L, Cohn AL, Hopkins JO , Irwin DH, Smith DA, Boyd TE, & Olsen MR. DN101-004: A multicenter, open label, dose ranging study of DN-101 and docetaxel in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. Proceedings of the American Society of Clinical Oncology 2007; 25: 430s (A#7685).

West H, Belt RJ, Wakelee HA, Monberg MJ, Frye LA, Ye Z, & Obasaju CK. Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): Final report of a phase II clinical trial. Proceedings of the American Society of Clinical Oncology 2006; 24: 393 (A#7116).

Hirsch FR, Franklin WA, McCoy J, Capuzzo F, Varella-Garcia M, Witta SE, Gumerlock P, West H, Gandara DR, & Bunn P.A, Jr. Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal. Proceedings of the American Society of Clinical Oncology 2006; 24: 382 (A#7072).

Heymach J, West H, Kerr R, Prager D, Sandler A, Herbst R, Stewart D, Dimery I, & Johnson B. ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized phase II study. Lung Cancer 2005; 49 (Suppl 2): S-247-248 (A#P-497).

Hyunh MT, Lehrenbacher L, West H, Davies A, Simmons J, Lara P, Yarorkovsky L, Russin M, Gandara DR, & Lau D. A multi-institution phase II trial of irinotecan and carboplatin for extensive or relapsed small cell lung cancer. Proceedings of the American Society of Clinical Oncology 2005; 23: 662 (#7169).

West H, Belt RJ, Wakelee HA, Bloss LP, Taylor L, Monberg MJ, Ye Z, & Obasaju CK. Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial. Proceedings of the American Society of Clinical Oncology 2005; 23: 645 (#7117).

Hirsch FR, Gandara DR, McCoy J, Crowley J, West H, Gumerlock PH, Bunn PA, Franklin WA, & Varella-Garcia M. Increased EGFR gene copy number detected by FISH is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126). Proceedings of the American Society of Clinical Oncology 2005; 23: 628 (#7030).

Gumerlock PH, Holland WS, Chen H, Franklin WA, Hirsch FR, Mack PC, Davies AM, West H, & Gandara DR. Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group trial S0126 of bronchioloalveolar carcinoma (BAC) patients treated with gefitinib. Proceedings of the American Society of Clinical Oncology 2005; 23: 623 (#7008).

Johnson BE, Ma P, West H, Kerr R, Prager D, Sandler A, Herbst RS, Stewart DJ, Dimery IW, & Heymach JV. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC. Proceedings of the American Society of Clinical Oncology 2005; 23: 645 (#7102).

Gold PJ, Refice S, & West H. Phase I trial of irinotecan and epirubicin in patients with advanced solid tumors. Proceedings of the American Society of Clinical Oncology 2005; 23: 619 (#2120).

Franklin WA, Chansky K , Gumerlock PH, Crowley J, Hirsch FR, West H, Crowley JJ, & Gandara DR. Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126). Proceedings of the American Society of Clinical Oncology 2004; 23: 619 (#7015).

West HL, Franklin WA, Gumerlock P, Vance RB, Lau DHM, McCoy J, Crowley J, & Gandara DR. Gefitinib (ZD1839) Therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. Proceedings of the American Society of Clinical Oncology 2004; 23: 618 (#7014).

West HL, Franklin WA, Gumerlock P, Vance RB, Lau DHM, Chansky K, Crowley J, McCoy J, & Gandara DR. ZD1839 (Iressa) in advanced bronchioloalveolar carcinoma (BAC): A preliminary report of SWOG S0126. Lung Cancer 2003; 41: S56.

Lau DHM, West H, Laptalo L, Geraghty E, Seibert A, Crowley J, & Gandara D. Computer-assisted image analysis of response in bronchioloalveolar carcinoma to ZD1839. Lung Cancer 2003; 41: S55.

Franklin WA, Gumerlock PH, Crowley J, Chansky K, West H, & Gandara DR. EGFR, HER2, and ERB-B pathway activation in bronchioloalveolar carcinoma (BAC): Analysis of SWOG 9714 and lung SPORE tissue samples. Proceedings of the American Society of Clinical Oncology 2003; 22: 620 (#2493).

Miller DL, Vallieres EC, West H, Okuno SH, Marks RS. Operative morbidity and mortality after induction chemotherapy and extrapleural pneumonectomy for malignant pleural mesothelioma. Proceedings of the European Association for Cardiothoracic Surgery 2002; 16.

West H, Yaziji H, Giarritta S, Livingston RB, Vallieres R, Wood DE, & Gown A. Overexpression of cyclooxygenase-2 (COX-2) is associated with increased aggressiveness of non-small cell lung cancer (NSCLC) tumors. Proceedings of the American Society of Clinical Oncology 2002; 21: 309a (#1235).

West H, Livingston R, Wood D, Vallieres E, Giarrita S, Yaziji H, & Gown AM. Overexpression of cyclooxygenase-2 (COX-2) is associated with more aggressive clinical behavior of non-small cell lung cancer. Lung Cancer 34 (Suppl 1); 45-46.

Vallieres E, West HL, Hunt K, Einck J, & Stelzer K. Induction chemotherapy, extrapleural pneumonectomy (EPP), and adjuvant radiation therapy for malignant pleural mesothelioma: a case series. Proceedings of the American Society of Clinical Oncology 2001; 20: 279b (#2867).

West HL, Livingston, RB, Wood DE, Vallieres E, Yaziji H, & Gown A. HER-2/neu (HER2), as assessed by immunohistochemistry (IHC), is rarely expressed in stage I resected non-small cell lung cancer (NSCLC) and does not predict clinical outcome. Proceedings of American Society of Clinical Oncology 2001; 20: 333a (#1327).

West HL, Taylor LP, & Jacobs AD. Association of angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) with progressive sensory polyneuropathy/ataxia: A case report. Blood, 1999; 94 Suppl 1: 293b.

West HL, Rebeck GW, Perls T, Sodhi P, Lipsitz L, & Hyman BT. The prevalence of apolipoprotein E4 in the oldest old: connections with Alzheimer’s disease. Neurology, 1994; 44: A325.

Hyman BT, West HL, Harr S, Gomez-Isla T, & Mui S. Quantitative neuropathology in Alzheimer’s disease: neuronal loss in high order association cortex parallels dementia. Neurobiology of Aging, 1994; 44: S141.

West HL, Rebeck GW, Growdon JH, & Hyman BT. Apolipoprotein E4 affects neuropathology but not clinical progression in Alzheimer’s disease. Neurobiology of Aging, 1994; 15: S28.

Hoebel BG, Mark GP, & West HL. Conditioned neurotransmitter release as measured by microdialysis. Clinical Neuropharmacology, 1992; 15 Suppl. 1A: 704A.

West HL, Robbins TW, & Everitt BE. AMPA-induced cholinergic lesions of the vertical limb of the diagonal band (VDB) impair performance of a conditioned visual discrimination (CVD) task. Society for Neuroscience Abstracts, 1991; 17: 138.

West HL, Schwartz DH, & Hoebel BG. Local injection of serotonin into the lateral hypothalamus suppresses food intake. Society for Neuroscience Abstracts, 1989; 15:1281.
________________________________________

PRESENTATIONS:

West H, Moon J, Hirsch F, Mack PC, Wozniak A, Redman M, & Gandara DR. The combination of erlotinib/bevacizumab in never-smokers with advanced lung adenocarcinoma: Southwest Oncology Group (SWOG) trial 0636. Talk delivered at 13th World Conference on Lung Cancer: Amsterdam, Netherlands, 7/11.

West H, Chansky K, Franklin WA, .Hirsch FR, Crowley JJ, Lau DH, & Gandara DR. Long-term survival with gefitinib (ZD 1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126. Poster presented at the American Society for Clinical Oncology Annual Conference: Chicago, IL, 6/2008.

West H, Lee S , Reyno L, Fehrenbacher L, Cohn AL, Hopkins JO, Irwin DH, Smith DA, Boyd TE, & Olsen MR. DN101-004: A multicenter, open label, dose ranging study of DN-101 and docetaxel in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. Talk delivered at 12th World Conference on Lung Cancer: Seoul, Korea, 9/2007.

West H, Lee S , Reyno L, Fehrenbacher L, Cohn AL, Hopkins JO , Irwin DH, Smith DA, Boyd TE, & Olsen MR. DN101-004: A multicenter, open label, dose ranging study of DN-101 and docetaxel in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. Poster presented at the American Society for Clinical Oncology Annual Conference: Chicago, IL, 6/2007.

West H, Belt RJ, Wakelee HA, Monberg MJ, Frye LA, Ye Z, & Obasaju CK. Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): Final report of a phase II clinical trial. Poster presented at the American Society for Clinical Oncology Annual Conference: Atlanta, GA, 6/2006.

West H, Belt RJ, Wakelee HA, Bloss LP, Taylor L, Monberg MJ, Ye Z, & Obasaju CK. Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial. Poster presented at the American Society for Clinical Oncology Annual Conference: Orlando, FL, 5/2005.

West HL, Franklin WA, Gumerlock P, Vance RB, Lau DHM, McCoy J, Crowley J, & Gandara DR. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. Talk delivered at the American Society for Clinical Oncology Annual Conference: New Orleans, LA, 6/2004.

West HL, Franklin WA, Gumerlock P, Vance RB, Lau DHM, McCoy J, Crowley J, & Gandara DR. Gefitinib (ZD1839) Therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. Talk delivered at Innovators in Lung Cancer conference: Boston, MA, 5/2004.

West HL, Franklin WA, Gumerlock P, Vance RB, Lau DHM, Chansky K, Crowley J, McCoy J, & Gandara DR. ZD1839 (Iressa) in advanced bronchioloalveolar carcinoma (BAC): A preliminary report of SWOG S0126. Talk delivered at 10th World Conference on Lung Cancer: Vancouver, BC, Canada, 8/2003.

West H, Franklin WA, Gumerlock PH, Lau DHM, Crowley J, Chansky K, Vance R, & Gandara DR. Gefitinib in bronchioloalveolar carcinoma (BAC): SWOG 0126 experience. Talk delivered at Fourth International Lung Cancer Congress: Maui, HI, 6/2003.

West H, Yaziji H, Giarritta S, Livingston RB, Vallieres R, Wood DE, & Gown A. Overexpression of cyclooxygenase-2 (COX-2) is associated with increased aggressiveness of non-small cell lung cancer (NSCLC) tumors. Poster presented at the American Society for Clinical Oncology Annual Conference: Orlando, FL, 5/2002.

West H, Yaziji H, Giarritta S, Livingston RB, Vallieres R, Wood DE, & Gown A. Overexpression of cyclooxygenase-2 (COX-2) is associated with increased aggressiveness of non-small cell lung cancer (NSCLC) tumors. Talk delivered at Innovators in Lung Cancer conference: Chicago, IL, 4/2002.

West HL, Livingston, RB, Wood DE, Vallieres E, Yaziji H, & Gown A. HER-2/neu (HER2), as assessed by immunohistochemistry (IHC), is rarely expressed in stage I resected non-small cell lung cancer (NSCLC) and does not predict clinical outcome. Poster presented at the American Society for Clinical Oncology Annual Conference: San Francisco, CA, 5/2001.

West HL. The apolipoprotein E e4 allele is a risk factor for development of Alzheimer’s disease but does not influence its clinical progression. Talk delivered at Howard Hughes Medical Institute Research Fellowship Conference: Washington, DC, 5/1994.

West HL, Rebeck GW, Perls TP, Lipsitz LA, Sodhi, P, & Hyman BT. Apolipoprotein E4 prevalence in the oldest old: Connections with Alzheimer’s disease. Talk delivered at American Academy of Neurologists Annual Conference: Washington, DC, 5/1994.

West HL, Robbins TW, & Everitt, BE. AMPA-induced cholinergic lesions of the vertical limb of the diagonal band (VDB) impair performance of a conditional visual discrimination (CVD) task. Poster presented at Society for Neuroscience Conference: New Orleans, LA, 11/1991.

West HL, Mark GP, & Hoebel BG. Effects of conditioned taste aversion (CTA) on serotonin release in the lateral hypothalamus and hippocampus. Poster presented at Society for Neuroscience Conference: St. Louis, MO, 11/1990.

West HL, Mark GP, & Hoebel. Effects of conditioned taste aversion acquisition and expression on serotonin release in the lateral hypothalamus and hippocampus as measured by microdialysis. Poster presented at New Jersey Neuropsychopharmacology Society Conference: Princeton, NJ, 5/1990.

West HL, Schwartz DH, & Hoebel BG. Local injection of serotonin into the lateral hypothalamus suppresses food intake. Poster presented at Society for Neuroscience Conference: Phoenix, AZ, 10/1989.

Specialties

Specialties
  • Oncology - Medical
Clinical Interests
  • Medical Oncologist
  • Mesothelioma
  • Testicle Cancer

Reviews

Patient Ratings and Comments
About Our Survey

The Patient Rating score is based on responses given during the CAHPS Patient Experience Survey. Responses are measured on a 10-point scale, with 10 being the best score. These scores are then translated to a 5-point scale in order to display results in a 5-star rating. Comments are also gathered from the same survey and displayed in their entirety with the exception of any language that may be considered slander, libel or contain private health information, which will be removed prior to publishing the comments.

4.7 out of 5 (32 Ratings, 5 Comments)

100

05/25/2015
A stellar institution.
Swedish Patient
100

04/26/2015
Dr West is the best!
Swedish Patient
100

04/20/2015
Dr. West and his nurse [...] are great care providers - what more can I say
Swedish Patient
100

04/13/2015
Doctor West has given excellent explanations of my situation and has been careful to give me treatments that are the least uncomfortable and yet effective.
Swedish Patient
100

03/25/2015
They treated me royally.
Swedish Patient